Fiscal 2021 was a defining year for Twist. Thank you, Angela, and good morning, everyone. Emily Leproust.Įmily Leproust - Chief Executive Officer and Co-Founder With that, I'll now turn the call over to our Chief Executive Officer and Co-Founder, Dr.
Twist bioscience update#
We disclaim any obligation to update any forward-looking statements except as required by law.
Twist bioscience full#
The forward-looking statements in this presentation are based on information available to us as of the date hereof and we cannot at this time predict the full extent of the ongoing impact of the COVID-19 pandemic and any resulting business or economic impact. These risks include those set forth in the press release we issued earlier today, as well as those more fully described in our filings with the Securities and Exchange Commission. Our expectations and beliefs regarding these matters may not materialize and actual results and financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements generally relate to future events or future financial or operating performance. The audio portion will be archived in the Investors section of our website and will be available for two weeks.ĭuring today's presentation, we will make forward-looking statements within the meaning of the U.S. As a reminder, this call is being recorded. Emily will come back to discuss our upcoming milestones and direction and then we'll open the call for questions. Jim will report on our financial and operational performance. Emily will begin with a review of our recent progress and Twist businesses. Emily Leproust, CEO and Co-Founder of Twist and Jim Thorburn, CFO of Twist. We issued our financial results release as well as the press release announcing we entered into an agreement to acquire Abveris this morning, both of which are available at our website at With me on today's call are Dr. I would like to thank all of you for joining us today for Twist Biosciences conference call to review our fiscal 2021 fourth quarter and full year financial results and business progress. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.Thank you, Michelle. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live event.
The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on Monday, May 23 at 9:15 a.m. SOUTH SAN FRANCISCO, Calif., May 18, 2022-( BUSINESS WIRE)-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M.
0 kommentar(er)
